Vaccine Dangers Interview Geert Vanden Bossche

Posted on 18th April, 2021


Mass Vaccination in a Pandemic - Likely to create more more viral variants in the process.

Benefits versus Risks: Interview with Geert Vanden Bossche


Interview on 06 March 2021 - Highlighting the principle of using a prophylactic vaccine in the midst of a pandemic.




0:00 - Intro

7:36 - Lockdowns

8:51 - Gaining immunity from exposure & immunological escape

11:17 - COVID vaccine

18:30 - COVID antibodies

19:55 - NK Cells

25:00 - Antigen-specific antibodies outcompete natural antibodies

28:51 - Highly-infectious strain

31:01 - Vaccine resistance in COVID pandemic

31:51 - More on immunological escape

32:59 - Geert Vanden Bossche’s thoughts on COVID vaccination

"Geert Vanden Bossche PhD, is an internationally recognised vaccine developer having worked as the head of the Vaccine Development Office at the German Centre for Infection Research. Coordinated Global Alliance for Vaccines and Immunisation's Ebola Vaccine Program and contributed to the implementation of an integrated vaccine work plan in collaboration with Global Health Partners (WHO, Bill & Melinda Gates Foundation, CDC, UNICEF), regulators (FDA) and vaccine manufacturers to enable timely deployment or stockpiling of Ebola vaccine candidates. Sharing his perspective on mass vaccination in COVID-19."



See also:

Make A Comment

Characters left: 2000

Comments (0)